Announcement • Nov 05
Onassis Holdings Corp. Announces Appointment of Esq. Paz Itzhaki-Weinberger to Its Advisory Board Onassis Holdings Corp. announced the appointment of Esq. Paz Itzhaki-Weinberger to its Advisory Board. Paz will lead the company's strategy on international law, trade, and cross border corporate affairs. Paz Itzhaki-Weinberger combines deep experience in technology, law, and international business. He has held senior roles at Microsoft Corporation, managed multiple hi-tech ventures. As both an engineer and a lawyer, he has practiced at one of Israel's leading law firms and founded PIWLAW, recognized among the Top 200 Law Firms Worldwide (2014–2025) by Legals Finest. Currently the CEO and Chairman of IWC Limited, Itzhaki-Weinberger previously led PatentsFund.com and continues to advise technology firms on IPO and M&A transactions. He holds degrees in Computer Science and Law and is fluent in English, Hebrew, Japanese, German, and Arabic. Itzhaki-Weinberger is a member of the Israel Bar Association, the American Bar Association International Law Division, and The Law Society of England and Wales, as well as a Senior Member of IEEE and a board member of the Israel-Britain Chamber of Commerce. Announcement • Oct 16
Onassis Holdings Corp. announced a financing transaction Onassis Holdings Corp. announced a private placement through Regulation D on October 15, 2025. Based on the Regulation D, the company reported a total offering amount of $10,000,000 and confirmed that the first sale has yet to occur with the full amount remaining to be sold. Announcement • Sep 24
Onassis Holdings Corp. (OTCPK : ONSS) agreed to acquire MGC Nutraceuticals d.o.o. from MGC Pharma (UK) Limited for $6 million. Onassis Holdings Corp. (OTCPK : ONSS) agreed to acquire MGC Nutraceuticals d.o.o. from MGC Pharma (UK) Limited for $6 million on June 18, 2020. MGC Pharma (UK) Limited is a wholly owned subsidiary of MGC Pharmaceuticals Limited (ASX : MXC). As part of consideration, $6 million worth of shares in Onassis Holdings Corp are to be issued to MGC Pharma (UK) Ltd. The shares to be issued to MGC Pharma (UK) Ltd will be valued at the Onassis $8.5 million raising price. MGC Nutraceuticals d.o.o. to purchase all CBD and raw material formulas from MGC Pharmaceuticals Limited for as long as MGC Pharmaceuticals Limited or its subsidiaries continue operating any production facilities in the EU – potential revenues from this supply would be determined in the future following MGC Pharmaceuticals Limited receiving purchase orders. The transaction is expected to close within 150 days of signing of this acquisition agreement upon completion of the settlement terms. The material settlement conditions are as follows :- Onassis has been deemed qualified by the Securities and Exchange Commission (the “SEC”) and has raised at least $2.5 million. Onassis has funded MGC Nutraceuticals with no less than $2.5 million in cash. MGC Pharma has the right to appoint one director to the Board of directors of Onassis. Onassis and MGC Nutraceuticals’ business and assets shall not have been adversely affected in any material way prior to the settlement. 
